PDS Biotechnology Corporation
PDSBHealthcare|Biotechnology|US
$1.23
+0.06 (+5.13%)
DCF Value
$0.14
Cash / Share
$0.10
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06790966 Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer | P3 | Terminated | 12 | RCT, Open-label | Pembrolizumab Monotherapy |
| NCT04260126 Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC | Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer | P2 | Completed | 95 | Open-label | — |
| NCT02065973 An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101 | High-risk HPV Infection and Biopsy-proven CIN1 | P1 | Completed | 12 | Open-label | R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7 |
| NCT07922382 Integrated Attachment Theory | Attachment Disorder | N/A | Not Yet Recruiting | 24 | RCT, Open-label | — |